echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The first! FDA approves innovative treatments for liver disease in children

    The first! FDA approves innovative treatments for liver disease in children

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Mirum Pharmaceuticals announced today that the US FDA has approved Livmarli (maralixibat) for the treatment of cholestatic pruritus in children with Alagille syndrome (ALGS) over 1 year old


    Alagille syndrome is a rare genetic disease.


    Livmarli is an oral selective apical sodium-dependent bile acid transporter (ASBT) inhibitor.


    ▲The mechanism of action of Livmarli (picture source: Mirum's official website)

    The approval of Livmarli is based on the results of a pivotal Phase 2b clinical trial.


    Reference materials:

    [1] US FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older.


    [2] Phase 2 placebo-controlled withdrawal study of the ASBT inhibitor maralixibat in children with Alagille syndrome, Retrieved October 28, 2019, from https://mirumpharma.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.